GNI Group Ltd.

Tokyo Stock Exchange 2160.T

GNI Group Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -48.49 M

GNI Group Ltd. Net Cash Used For Investing Activities is USD -48.49 M for the year ending December 31, 2023, a -54.51% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

GNI Group Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -31.38 M, a -1,286.17% change year over year.
GNI Group Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -2.26 M, a -141.03% change year over year.
GNI Group Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD 5.52 M, a 491.69% change year over year.
GNI Group Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -1.41 M, a 86.06% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

Tokyo Stock Exchange: 2160.T

GNI Group Ltd.

CEO	Dr. Ying Luo Ph.D.
IPO Date	Aug. 31, 2007
Location	Japan
Headquarters	Nihonbashi-Honcho YS Building
Employees	843
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Chemicals & Advanced Materials Clinical Trials Composite Materials Plastics Tobacco

Description

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years